Due to its blockage of the cytokine-induced damage, dupilumab is commonly used to treat diseases that utilize the IL-4 and IL-13 pathway, including asthma, atopic dermatitis, chronic sinusitis with nasal polyps, and eosinophilic esophagitis. Here, IL13 is linked to atopic eczema.